Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
103 Results for "
SMA
" in MedChemExpress (MCE) Product Catalog:
Products (103)
103 Results for "SMA" in MCE Product Catalog:
Cat. No.: HY-184738
CAS No.: 2103516-38-5
Target:
Research Areas:
Antifibrotic agent 3 is an orally active antifibrotic agent. Antifibrotic agent 3 reduces hepatic stellate cell activation by downregulating the expression of Collagen I and α-SMA. Antifibrotic agent 3 inhibits liver fibrosis in bile duct ligation and carbon tetrachloride-induced liver fibrosis models. Antifibrotic agent 3 can be used for the research of liver fibrosis .
Cat. No.: HY-187994
Target:
Research Areas:
Antifibrotic agent 4 is an antifibrotic agent. Antifibrotic agent 4 inhibits the expression of the fibrotic markers α-SMA and COL1A1 in hepatic stellate cells by binding to FGFR4 and reducing its autophosphorylation, ameliorates liver injury and collagen deposition in mouse models of liver fibrosis, and does not inhibit the hERG potassium channel. Antifibrotic agent 4 can be used in the research of liver fibrosis .
Cat. No.: HY-184278
Target:
Research Areas:
ATX-IN-28 is an orally active autotaxin (ATX) inhibitor with an IC50 of 13.7 nM. ATX-IN-28 downregulates the expression of pro-fibrotic α-SMA, ameliorates pathological damage of lung tissues in a bleomycin (HY-108345)-induced mouse model of pulmonary fibrosis, and reduces collagen deposition. ATX-IN-28 can be used for research related to idiopathic pulmonary fibrosis .
Cat. No.: HY-P704125
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: SMN1; Survival Of Motor Neuron 2 Isoform D2A2B345; Prev. SMA@; Survival Of Motor Neuron 2 Isoform D2B3457; Prev. SMA; Survival Of Motor Neuron 1 Isoform D2B3457; SMNT; Survival Of Motor Neuron 2 Isoform D2A3457; Survival Motor Neuron Protein; Survival Of
Species:
Human
Source:
E. coli
Cat. No.: HY-181439
CAS No.: 2344793-72-0
Research Areas:
SNX3-IN-1 is a sorting nexin 3 (SNX3) inhibitor. SNX3-IN-1 reduces SNX3 protein expression and inhibits SNX3-mediated activation of the Wnt/β-catenin signaling pathway. SNX3-IN-1 inhibits the proliferation and migration of pulmonary fibrosis-related cells, and decreases the expression of fibrosis markers α-SMA and COL-1. SNX3-IN-1 can be used in research related to pulmonary fibrosis .
Cat. No.: HY-111520R
CAS No.: 1562333-92-9
Target:
Research Areas:
NVS-SM2 (Standard) is the analytical standard of NVS-SM2 (HY-111520). This product is intended for research and analytical applications. NVS-SM2 is a potent, orally active and brain-penetrant SMN2 splicing enhancer with an EC50 of 2 nM for SMN. NVS-SM2 enhances U1-pre-mRNA association. NVS-SM2 promotes exon 7 inclusion and restores normal survival motor neuron (SMN) protein expression. NVS-SM2 can be used for spinal muscular atrophy (SMA) research .
Cat. No.: HY-P992379
Synonyms: BAG3-H2L4
Target:
Research Areas:
Cat. No.: HY-180271
Research Areas:
Xanthine oxidase-IN-21, a Genipin (HY-17389) derivative, is an orally active mixed competitive xanthine oxidase (XOD) inhibitor with an IC50 of 0.68 μM. Xanthine oxidase-IN-21 reduces renal fibrosis by decreasing α-SMA expression and suppresses pro-inflammatory cytokines IL-1β, IL-6, and TNF-α through NF-κB pathway regulation. Xanthine oxidase-IN-21 also inhibits URAT1 and GLUT9 expression, promoting uric acid excretion and lowering serum uric acid levels. Xanthine oxidase-IN-21 shows significantly hepatorenal protection activity. Xanthine oxidase-IN-21 can be used for the research of hyperuricemia .
Cat. No.: HY-16342
CAS No.: 827034-92-4
Target:
Research Areas:
NA808 is an Serine Palmitoyltransferase (SPT) inhibitor. NA808 reduces sphingomyelin synthesis, inhibits its activation in hepatic stellate cells, and decreases the expression of α-SMA protein and mRNA, as well as collagen 1A1 mRNA (IC50 0.16, 0.12, and 0.11 μM, respectively). NA808 inhibits HCV replication and reduces NS3 and RdRp protein expression in HCV replicon cells without significant cytotoxicity and exhibits almost no immunosuppressive effect at effective concentrations. NA808 demonstrates broad-spectrum antiviral activity in humanized chimeric liver mice infected with various HCV genotypes, and dose-dependently reduces serum and hepatic HCV RNA levels. NA808 can be used for research on non-alcoholic steatohepatitis and hepatitis C virus infection .
Cat. No.: HY-180585
Research Areas:
LOXL2/sGC modulator-2 (Compound 9k) is a selective and orally active lysyl oxidase-like 2 (LOXL2) and soluble guanylate cyclase (sGC) dual-target regulator. LOXL2/sGC modulator-2 shows inhibitory activity for LOXL2 with an IC50 of 0.1 μM and can activate sGC. LOXL2/sGC modulator-2 can ameliorate vascular remodeling and reduce pulmonary artery pressure. LOXL2/sGC modulator-2 can downregulate PKG1, PCNA, α-SMA, collagen I and fibronectin levels. LOXL2/sGC modulator-2 can be used for the research of pulmonary arterial hypertension .
Cat. No.: HY-102020A
CAS No.: 1466525-84-7
Target:
Research Areas:
RG3039 hydrochloride is an orally active, blood-brain barrier-permeable DcpS inhibitor with an IC50 of 4.2 nM against hDcpS. RG3039 hydrochloride inhibits the decapping activity of DcpS and maintains DcpS in a catalytically inactive conformation in the central nervous system and other tissues. RG3039 hydrochloride extends survival and improves function in spinal muscular atrophy mice. RG3039 hydrochloride is applicable to research related to spinal muscular atrophy .
Cat. No.: HY-P706159
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: SMAD3; MAD, Mothers Against Decapentaplegic Homolog 3; Prev. MADH3; SMAD, Mothers Against DPP Homolog 3; JV15-2; SMA- And MAD-Related Protein 3; HsT17436; Mothers Against DPP Homolog; Mothers Against Decapentaplegic Homolog 3; Mad Protein Homolog; Mothers
Species:
Rat
Mouse
Human
Source:
Sf9 insect cells
Cat. No.: HY-124640
CAS No.: 1537150-15-4
Target:
Research Areas:
SMN2 modulator-1 is a brain-penetrant survival motor neuron (SMN) modulator. SMN2 modulator-1 post-translationally stabilizes SMN protein and increases SMN protein levels independent of SMN2 transcription. SMN2 modulator-1 can be used for the research of spinal muscular atrophy[1].
Cat. No.: HY-P73636
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: SMAD3; MAD, Mothers Against Decapentaplegic Homolog 3; Prev. MADH3; SMAD, Mothers Against DPP Homolog 3; JV15-2; SMA- And MAD-Related Protein 3; HsT17436; Mothers Against DPP Homolog; Mothers Against Decapentaplegic Homolog 3; Mad Protein Homolog; Mothers
Species:
Rat
Mouse
Human
Source:
Sf9 insect cells
Cat. No.: HY-L086
3,759 compounds
Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.
MCE offers a unique collection of 3,759 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.
Cat. No.: HY-P86727
Synonyms: alpha sarcomeric Actin; alpha smooth muscle Actin; Actin alpha; ASMA; ASM-A; alpha-SMA; alpha SMA; AAT6; ACTA2; Actin alpha 2 smooth muscle aorta; Actin aortic smooth muscle; ACTSA; ACTVS; alpha 2 actin; alpha-actin 2; Cell growth inhibiting gene 46 protein; Growth inhibiting gene 46; ACTA_HUMAN; Actin alpha 2 smooth muscle aorta; Actin aortic smooth muscle; Actin, aortic smooth muscle; alpha 2 actin; alpha actin 2; alpha cardiac actin; alpha-actin 2; alpha-actin-2; Cell growth inhibiting gene 46 protein; Cell growth-inhibiting gene 46 protein; Growth inhibiting gene 46; MYMY5
Cat. No.: HY-P86727A
Synonyms: alpha sarcomeric Actin; alpha smooth muscle Actin; Actin alpha; ASMA; ASM-A; alpha-SMA; alpha SMA; AAT6; ACTA2; Actin alpha 2 smooth muscle aorta; Actin aortic smooth muscle; ACTSA; ACTVS; alpha 2 actin; alpha-actin 2; Cell growth inhibiting gene 46 protein; Growth inhibiting gene 46; ACTA_HUMAN; Actin alpha 2 smooth muscle aorta; Actin aortic smooth muscle; Actin, aortic smooth muscle; alpha 2 actin; alpha actin 2; alpha cardiac actin; alpha-actin 2; alpha-actin-2; Cell growth inhibiting gene 46 protein; Cell growth-inhibiting gene 46 protein; Growth inhibiting gene 46; MYMY5
Cat. No.: HY-P83739
Synonyms: alpha sarcomeric Actin; alpha smooth muscle Actin; Actin alpha; ASMA; ASM-A; alpha-SMA; alpha SMA; AAT6; ACTA2; Actin alpha 2 smooth muscle aorta; Actin aortic smooth muscle; ACTSA; ACTVS; Alpha 2 actin; Alpha-actin 2; Cell growth inhibiting gene 46 protein; Growth inhibiting gene 46; ACTA_HUMAN; Actin alpha 2 smooth muscle aorta; Actin aortic smooth muscle; Actin, aortic smooth muscle; Alpha 2 actin; Alpha actin 2; Alpha cardiac actin; Alpha-actin 2; Alpha-actin-2; Cell growth inhibiting gene 46 protein; Cell growth-inhibiting gene 46 protein; Growth inhibiting gene 46; MYMY5 α-Smooth Muscle Actin; α Smooth Muscle Actin;
Cat. No.: HY-P85827
Synonyms: a actin; AAT6; ACTA; ACT; ACTA3; ACTE; ACTG2; ACTH_HUMAN; Actin; Actin gamma 2 smooth muscle enteric; Actin gamma enteric smooth muscle; Actin like protein; ACTL3; ACTSG; Alpha actin 3; Alpha-actin-3; Gamma 2 actin; Gamma-2-actin; gamma-enteric smooth muscle; Smooth muscle gamma actin; Smooth muscle gamma-actin
Cat. No.: HY-171881
CAS No.: 864686-48-6
Research Areas:
BI-5521 is an orally active GSK-3 inhibitor with an IC50 of 1.1 nM against GSK-3β. BI-5521 targets the two GSK-3 isoforms with similar potency and exhibits potent inhibitory activity against DYRK1A. By modulating GSK-3 activity, BI-5521 inhibits tumor proliferation and cancer cell growth, exerts cytotoxic effects, and reduces cancer cell viability. It shows consistent chemosensitivity across all subtypes of rhabdomyosarcoma, produces synergistic growth inhibitory effects when combined with SOS1 inhibitors, reduces oral glucose levels, regulates the myofibroblast differentiation pathway, decreases the nuclear localization of YAP/SMAD2/3, and lowers the positive rate of α-SMA in fibroblasts without affecting the apoptosis of CD4 + T cells. BI-5521 can be used in the research of non-small cell lung cancer, pleomorphic rhabdomyosarcoma, type 2 diabetes, pancreatic ductal adenocarcinoma, Alzheimer's disease, bipolar disorder, and metabolic dysfunction-associated steatotic liver disease .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
